share_log

翰森製藥：二零二四年中期報告

HANSOH PHARMA: INTERIM REPORT 2024

HKEX ·  Sep 26 16:49

Summary by Moomoo AI

翰森制藥公布截至2024年6月30日止六個月的中期財務報告，顯示公司收入約人民幣65.06億元，同比增長約44.2%；創新藥與合作產品收入約人民幣50.32億元，同比增長約80.6%，佔收入比例約77.4%。研發開支約人民幣11.96億元，同比增長約28.7%，佔收入比例約18.4%。期內溢利約人民幣27.26億元，同比增長約111.5%；每股基本盈利約人民幣0.46元，同比增長約111.4%。董事會宣佈派發中期股息每股20.10港仙。公司為中國領先的以研發創新為驅動的製藥公司，已獲批上市七款創新藥，均已被納入國家醫保目錄。報告期內，公司自主研發的多款新藥獲得國家藥監局核准簽發的藥物臨床試驗批准通知書，並與多家生物製藥企業訂立許可協議。
翰森制藥公布截至2024年6月30日止六個月的中期財務報告，顯示公司收入約人民幣65.06億元，同比增長約44.2%；創新藥與合作產品收入約人民幣50.32億元，同比增長約80.6%，佔收入比例約77.4%。研發開支約人民幣11.96億元，同比增長約28.7%，佔收入比例約18.4%。期內溢利約人民幣27.26億元，同比增長約111.5%；每股基本盈利約人民幣0.46元，同比增長約111.4%。董事會宣佈派發中期股息每股20.10港仙。公司為中國領先的以研發創新為驅動的製藥公司，已獲批上市七款創新藥，均已被納入國家醫保目錄。報告期內，公司自主研發的多款新藥獲得國家藥監局核准簽發的藥物臨床試驗批准通知書，並與多家生物製藥企業訂立許可協議。
Hansen Pharmaceutical announced its interim financial report for the six months ended June 30, 2024, showing a revenue of approximately 6.506 billion yuan, a year-on-year increase of about 44.2%; revenue from innovative drugs and collaborative products is approximately 5.032 billion yuan, a year-on-year increase of about 80.6%, accounting for approximately 77.4% of the revenue. Research and development expenses are approximately 1.196 billion yuan, a year-on-year increase of about 28.7%, accounting for approximately 18.4% of the revenue. The net profit for the period is approximately 2.726 billion yuan, a year-on-year increase of about 111.5%; earnings per share is approximately 0.46 yuan, a year-on-year increase of about 111.4%. The board of directors announced an interim dividend of HK$0.201 per share. The company is a leading pharmaceutical...Show More
Hansen Pharmaceutical announced its interim financial report for the six months ended June 30, 2024, showing a revenue of approximately 6.506 billion yuan, a year-on-year increase of about 44.2%; revenue from innovative drugs and collaborative products is approximately 5.032 billion yuan, a year-on-year increase of about 80.6%, accounting for approximately 77.4% of the revenue. Research and development expenses are approximately 1.196 billion yuan, a year-on-year increase of about 28.7%, accounting for approximately 18.4% of the revenue. The net profit for the period is approximately 2.726 billion yuan, a year-on-year increase of about 111.5%; earnings per share is approximately 0.46 yuan, a year-on-year increase of about 111.4%. The board of directors announced an interim dividend of HK$0.201 per share. The company is a leading pharmaceutical company in China driven by research and innovation, with seven innovative drugs approved for market launch, all included in the national medical insurance catalog. During the reporting period, several new drugs developed independently by the company received drug clinical trial approval notices issued by the National Medical Products Administration and entered into licensing agreements with multiple biopharmaceutical companies.

This announcement is a separate document:

Doc 1     View Translation

Disclaimer: This content is for informational and educational purposes only and does not constitute a recommendation or endorsement of any specific investment or investment strategy. Read more
    Heat List
    US
    SymbolLatest Price% Chg

    No Data

    Hot News
    Updated